RxDoctor Payments Data

Ying Zhang, NP

Adult Health · Arcadia, CANPI 1982174504

Payments from drug & device makers

$760in general payments, 2019–2025

Across 28 payments — averaging $27.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$172
  • Neurocrine Biosciences, Inc.$143
  • Lilly USA, LLC$114
  • Corcept Therapeutics$70
  • Vanda Pharmaceuticals Inc.$52
  • Novo Nordisk$47
  • plus $162 from 5 others

What the payments were for

  • Food & beverage$760100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$760 in reported general payments places this provider in the 65th percentile of 785 adult health providers in California.

See all adult health providers in California

Medicare billing

Part B allowed, 2024
$153,186
Medicare patients
287
Services billed
2,169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate39$303,785
JardianceEmpagliflozin165$80,827
EliquisApixaban50$32,538
JanuviaSitagliptin Phosphate44$30,405
TrulicityDulaglutide30$29,479
MyrbetriqMirabegron75$19,820
XareltoRivaroxaban24$14,841
FarxigaDapagliflozin Propanediol14$11,318
Atorvastatin Calcium411$5,103
Memantine Hcl ErMemantine Hcl26$4,465
Levothyroxine Sodium432$4,426
Potassium Chloride127$4,351
LantusInsulin Glargine,hum.Rec.Anlog45$3,215
Memantine Hcl167$2,955
Metformin Hcl217$2,787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$143$303,78539 claims
Lilly USA, LLCTrulicity$114$29,47930 claims
Astellas Pharma US IncMyrbetriq$37$19,82075 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 785 adult health providers in California.

Other adult health in Arcadia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →